Meet 5 featured patients and hear their stories           Dear friends,   Treatment options are being expanded to meet the needs of our community. In this special edition of the Communiqué, we update you with a message from Bayer about KOVALTRY. This includes stories from patients, some of whom I know personally! Please read and discuss with your healthcare team.       Please visit www.kovaltry-us.com to learn more about KOVALTRY or to contact your local rep.     To learn more about LA Kelley Communications, please read our newsletter, PEN, available at www.kelleycom.com.     Warm regards, Laurie       LA Kelley Communications, Inc. always advises you to be a savvy consumer when contacting any company; do not reveal identifying information against your will. When you click on the links in this HTML file, you will be directed to the KOVALTRY® website. If you do not wish to receive future direct mail from us about new services and programs, please contact us at 97‍8-35‍2-76‍57 or info@kelleycom.com at once. This letter and its contents are being mailed by LA Kelley Communications with funding from Bayer. The recipient's name and address have not been shown to any third parties, including Bayer, and strict confidentiality has been preserved.         SELECTED IMPORTANT SAFETY INFORMATION     You should not use KOVALTRY® if you are allergic to rodents (like mice and hamsters) or any ingredients in KOVALTRY®. Continue reading below       KOVALTRY® Conversations: Real patients talk about living with hemophilia A and treatment with KOVALTRY®     See all their stories >             Seth K, 25   Basketball coach Prophylaxis 2x/week   Jason C, 37   Father of four Prophylaxis 3x/week           Seth P, 33   Avid runner Prophylaxis   Evan K, 18, & Lorie K, Mother   College student Prophylaxis           Adolescent and adult dosing for KOVALTRY®       20 to 40 IU/kg of body weight 2x/week or 3x/week.         Justin C, 39   Frequent traveler Prophylaxis 3x/week       Product choice is a decision that should be based on an individual's needs. These are some stories of patients using KOVALTRY®, but everyone's experience is different. Consult with your healthcare provider to see if KOVALTRY® is right for you.       INDICATIONS     • KOVALTRY® is a medicine used to replace clotting factor (Factor VIII or antihemophilic factor) that is missing in people with hemophilia A.   • KOVALTRY® is used to treat and control bleeding in adults and children with hemophilia A. KOVALTRY® can reduce the number of bleeding episodes in adults and children with hemophilia A when used regularly (prophylaxis). Your healthcare provider may give you KOVALTRY® when you have surgery.   • KOVALTRY® is not used to treat von Willebrand Disease.       IMPORTANT SAFETY INFORMATION     • You should not use KOVALTRY® if you are allergic to rodents (like mice and hamsters) or any ingredients in KOVALTRY®.   • Tell your healthcare provider if you have heart disease or are at risk for heart disease.   • The common side effects of KOVALTRY® are headache, fever, and itchy rash.   • Allergic reactions may occur with KOVALTRY®. Call your healthcare provider right away and stop treatment if you get tightness of the chest or throat, dizziness, decrease in blood pressure, and nausea.   • Your body can also make antibodies, called "inhibitors," against KOVALTRY®, which may stop KOVALTRY® from working properly. Consult with your healthcare provider to make sure you are carefully monitored with blood tests for the development of inhibitors to Factor VIII.   • Tell your healthcare provider about any side effect that bothers you or that does not go away.   • Call your healthcare provider right away if bleeding is not controlled after using KOVALTRY®.       For additional important risk and use information, please click here for full Prescribing Information.       You are encouraged to report negative side effects or quality complaints of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-8‍00-F‍DA-10‍88.             Bayer, the Bayer Cross, and KOVALTRY are registered trademarks of Bayer.     © 2017 Bayer. All rights reserved. 04‍/‍17 PP-675-US-0802       Please note this email is not monitored for replies. If you would like to contact us, please visit our website.